Send to

Choose Destination
J Pediatr Gastroenterol Nutr. 2020 Feb;70(2):247-251. doi: 10.1097/MPG.0000000000002575.

Severe Abdominal Manifestations in Juvenile Dermatomyositis.

Author information

Laboratoire d'Immunogénétique des maladies auto-immunes de l'enfant, Institut Imagine, INSERM U 1163.
Université de Paris.
Service de Neurophysiologie clinique, Centre de Référence des Maladies Neuromusculaires.
Service de Gastroentérologie et d'Hépatologie pédiatrique.
UF d'Hépatologie pédiatrique, Centre National de Référence Maladies Rares AVB-Cholestases génétiques, Hôpital Necker, APHP.
Equipe Contrôle de la croissance cellulaire par les nutriments, Institut Necker Enfants-Malades, INSERM U1151.
Service d'anatomo-pathologie.
Service d'Immunologie, Hématologie et Rhumatologie pédiatrique, centre de référence national des maladies rhumatologiques et systémiques auto-immunes rares pédiatriques (RAISE).
Service de Dermatologie et Dermatologie Pédiatrique.
Service d'Imagerie Pédiatrique, Hôpital Necker, APHP, Paris, France.


Juvenile dermatomyositis (JDM) is a rare and heterogeneous pediatric-onset idiopathic inflammatory myopathy. Gastrointestinal (GI) involvement occurs in 22% to 37% of JDM patients but has only been described in case reports. In this retrospective, single-center, observational study, we aimed to assess the causes and management of severe GI manifestations in JDM patients. We studied a cohort of 9 patients among 110 JDM patients followed during the study period (8.3%). The GI complications were related to JDM in most cases (17/19), with digestive tract involvement (n = 10), acute pancreatitis (n = 4), and hepatitis (n = 3). Three patients died from refractory JDM 2.9 years (2-3.6) after the JDM diagnosis. We highlight the need to consider pancreatitis as a main diagnostic factor in JDM patients with severe GI manifestations and the requirement of early aggressive treatment for these patients.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center